ClinicalTrials.gg
RecruitingNCT07434089Updated Feb 25, 2026

Impact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease

An interventional study of C-Mill technology treadmill equipped with semi-immersive VR and C-Mill treatment without semi-immersive virtual reality (VR) in Parkinson Disease, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.

Planned enrollment
7th of 13
60 · median 60
Started
2025
with 3 others
No phase
13 of 13
6 open now
Registered
13th of 13
by date

Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 13 with no phase, and was the 13th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, or all of them as a file.
02

Study summary

The GM-REHAB-2025 study aims to evaluate the impact of physiotherapy interventions using the C-Mill treadmill, with and without semi-immersive virtual reality, on gut microbiota and metabolic parameters in patients with Parkinson's disease. Three groups will be involved: one undergoing conventional physiotherapy, one treated with the C-Mill without virtual reality (VR), and one treated with C-Mill technology combined with VR. Clinical assessments and the collection of biological samples (stool, serum, and plasma) will be carried out at three time points: at baseline, at the end of treatment (21 days), and after 3 months.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PD according to the Movement Disorder Society Clinical
  • Diagnostic Criteria for Parkinson's Disease
  • Age comprised between 40 to 70 years
  • Patients with moderate to advanced disease (2 ≤ Hoehn and Yahr classification grade ≤ 4)
  • Individuals able to walk independently (FAC > 2)

Exclusion criteria

Exclusion Criteria:

  • PD patients with (1) weight > 135 kg and Height > 200 cm
  • Open lesions or bandages whether in contact with the harness of C-Mill strumentation
  • chronic gastro-intestinal (GI) disease including malabsorption;
  • clinical history of gastric lesions, gastro-resection or major intestinal surgery;
  • systemic and/or neurologic infectious, inflammatory, or diseases of gastro-intestinal (GI) eg. Chron disease;
  • Acute GI phlogosis or GI disease in the last 4 weeks before recruitment;
  • Use of domperidone, or any drug potentially affecting gastrointestinal motility and integrity;
  • Use, in the last 4 weeks preceding the recruitment and until t2, of pre-probiotics or therapy based upon , nonsteroidal anti-inflammatory drugs, antibiotics or antifungals;
  • anamnesis suggestive of GI cancer pathology.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    C-mill + VR treated

    includes 20 patients with PD undergoing C-Mill treatment combined with semi-immersive virtual reality (VR). This group will participate in 12 training sessions, each lasting 45 minutes, four times a week for three weeks. Gait training in each session will include exercises such as path with obstacles, tandem walking, slalom, and walking at varying speeds, all enhanced with semi-immersive VR scenarios projected on the treadmill's floor. The VR component will feature visual obstacles, such as virtual traffic cones or country paths, in conjunction with audio-visual stimuli to promote engagement and guide movement.

    Device: C-Mill technology treadmill equipped with semi-immersive VR

  • Experimental
    C-Mill treated

    Consists of 20 patients with Parkinson's Disease (PD) undergoing C-Mill treatment as a standalone therapy, without the integration of virtual reality (VR). Participants will complete 12 training sessions, each lasting 45 minutes, four times a week for three weeks. The training sessions will include exercises such as tandem walking, slalom walking, obstacle courses, and walking at varying speeds, all designed to enhance gait and balance.

    Device: C-Mill treatment without semi-immersive virtual reality (VR)

  • Experimental
    Conventional physiotherapy treated

    Consists of 20 patients with PD, who will undergo conventional physiotherapy training under the manual guidance and supervision of a physiotherapist. The rehabilitation program will include weight-shifting exercises, as well as monopodal and bipodal balance exercises. Gait training will incorporate obstacle courses (e.g., bricks, boxes) of varying shapes and colors, or paths created by the physiotherapist using furniture and equipment (e.g., chairs, traffic cones, sandbags). Patients will also perform slalom walking exercises, with auditory stimuli (e.g., music, therapist's voice) and visual cues (e.g., colored tape on the floor) to guide the exercises, adjusting their walking speed based on the auditory cues provided by the therapist.

    Other: Conventional physiotherapy training

Interventions

  • DeviceC-Mill technology treadmill equipped with semi-immersive VR

    C-Mill treatment combined with semi-immersive virtual reality (VR). The VR component will feature visual obstacles, such as virtual traffic cones or country paths, in conjunction with audio-visual stimuli to promote engagement and guide movement.

  • DeviceC-Mill treatment without semi-immersive virtual reality (VR)

    C-Mill treatment will be administrated as a standalone therapy, without the integration of virtual reality (VR).

  • OtherConventional physiotherapy training

    Will be carried under the manual guidance and supervision of a physiotherapist. The rehabilitation program will include weight-shifting exercises, as well as monopodal and bipodal balance exercises.

06

What researchers measure

Primary outcomes

  1. Relative abundance of bacterial and fungal taxa in fecal samples

    Relative abundance of bacterial and fungal taxa determined by sequencing the V3-V4 regions of the 16S rRNA and ITS1-IT2 regions from fecal samples. Unit of measurement: percentage of total sequencing reads(%).

    Time frame: From enrollment to the 3 months follow-up

  2. Alpha Diversity of the Gut Microbiota

    Within-sample microbial diversity derived from sequencing of the V3-V4 regions of the 16S rRNA gene and ITS1-ITS2 regions from fecal samples, expressed as an alpha diversity index. Unit of Measure: alpha diversity index value. Higher values indicate greater microbial diversity.

    Time frame: From enrollment to the 3 months follow-up

  3. Beta Diversity of the Gut Microbiota

    Between-sample microbial community derived from the sequencing of V3-V4 regions of the 16S rRNA and ITS1-ITS2 and expressed as a beta diversity distance. Unit of Measure: beta diversity distance. Higher values indicate greater dissimilarity between samples.

    Time frame: From enrollment to the 3 months follow-up

  4. Distance Covered During the 6-Minute Walk Test

    Functional walking capacity measured as the total distance walked during the 6-Minute Walk Test. Unit of Measure: meters. Higher values indicate better walking capacity.

    Time frame: From enrollment to the 3 months follow-up

  5. Time Required to Complete the 10-Meter Walk Test

    Walking ability assessed by measuring the time required to walk 10 meters at usual pace. Unit of Measure: seconds. Lower values indicate better walking performance.

    Time frame: From enrollment to the 3 months follow-up

  6. Time Required to Complete the Timed Up and Go Test

    Mobility and fall risk assessed by the time needed to stand up, walk 3 meters, turn, return, and sit down. Unit of Measure: seconds. Lower values indicate better functional mobility.

    Time frame: From enrollment to the 3 months follow-up

  7. Balance Performance Assessed by the Berg Balance Scale

    Balance measured using the Berg Balance Scale (range: 0-56). Higher scores indicate better balance and lower fall risk. Unit of Measure: total score.

    Time frame: From enrollment to the 3 months follow-up

  8. Balance and Gait Performance Assessed by the Tinetti Scale

    Balance and gait evaluated using the Tinetti Scale (range: 0-29). Higher scores indicate better mobility and lower fall risk. Unit of Measure: total score.

    Time frame: From enrollment to the 3 months follow-up

  9. Fear of Falling Assessed by the Short Falls Efficacy Scale-International

    Concern about falling measured using the Short Falls Efficacy Scale-International (range: 7-28). Higher scores indicate greater fear of falling. Unit of Measure: total score.

    Time frame: From enrollment to the 3 months follow-up

  10. Motor Symptom Severity Assessed by the MDS-UPDRS Part III (Motor Examination)

    Motor impairment evaluated using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, the Motor Examination section. Total score range from 0 to 132. Unit of Measure: total score. Higher scores indicate worse motor impairment.

    Time frame: From enrollment to the 3 months follow-up

  11. Functional Independence Assessed by the Functional Independence Measure

    Global functional status assessed using the Functional Independence Measure (range: 18-126). Higher scores indicate greater independence in daily activities. Unit of Measure: total score.

    Time frame: From enrollment to the 3 months follow-up

  12. Severity of Constipation Assessed by the Constipation Scoring System

    Constipation severity measured using the Constipation Scoring System questionnaire (range: 0-30). Higher scores indicate more severe constipation. Unit of Measure: total score.

    Time frame: From enrollment to the 3 months follow-up

Secondary outcomes

  1. Serum Concentration of TNF-α

    Serum TNF-α, a key pro-inflammatory cytokine, measured by ELISA to assess systemic inflammatory activation. Unit of Measure: pg/mL

    Time frame: From enrollment to the 3 months follow-up

  2. Serum Concentration of IL-1β

    Serum IL-1β, a pro-inflammatory cytokine involved in immune response, measured by ELISA. Unit of Measure: pg/mL

    Time frame: From enrollment to the 3 months follow-up

  3. Serum Concentration of IL-6

    Serum IL-6, a pro-inflammatory cytokine that mediates systemic inflammation, measured by ELISA. Unit of Measure: pg/mL

    Time frame: From enrollment to the 3 months follow-up

  4. Serum Concentration of IL-10

    Serum IL-10, an anti-inflammatory cytokine that regulates immune responses, measured by ELISA. Unit of Measure: pg/mL

    Time frame: From enrollment to the 3 months follow-up

  5. Serum Concentration of IL-4

    Serum IL-4, an anti-inflammatory cytokine involved in immune modulation, measured by ELISA. Unit of Measure: pg/mL

    Time frame: From enrollment to the 3 months follow-up

  6. Serum Concentration of FNDC5

    Serum FNDC5, a metabolic peptide measured by ELISA. Unit of Measure: ng/mL

    Time frame: From enrollment to the 3 months follow-up

  7. Serum Concentration of Adiponectin

    Serum Adiponectin, a metabolic peptide measured by ELISA. Unit of Measure: ng/mL

    Time frame: From enrollment to the 3 months follow-up

  8. Serum Concentration of Reduced Glutathione

    Serum Reduced Glutathione (GSH), a key antioxidant reflecting oxidative stress status, measured by ELISA. Unit of Measure: µmol/L

    Time frame: From enrollment to the 3 months follow-up

  9. Serum Concentration of Oxidized Glutathione

    Serum Oxidized Glutathione (GSSG), the oxidized form of glutathione indicating oxidative stress, measured by ELISA. Unit of Measure: µmol/L

    Time frame: From enrollment to the 3 months follow-up

  10. Serum Concentration of High-Sensitivity C-Reactive Protein

    Serum High-Sensitivity C-Reactive Protein (hs-CRP), an acute-phase protein reflecting systemic inflammation, measured by ELISA. Unit of Measure: mg/L

    Time frame: From enrollment to the 3 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pullia M, Ciatto L, Andronaco G, Donato C, Aliotta RE, Quartarone A, De Cola MC, Bonanno M, Calabro RS, Cellini R. Treadmill Training Plus Semi-Immersive Virtual Reality in Parkinson's Disease: Results from a Pilot Study. Brain Sci. 2023 Sep 12;13(9):1312. doi: 10.3390/brainsci13091312. PubMed 37759913 ↗
  • Malik AN, Tariq H, Afridi A, Rathore FA. Technological advancements in stroke rehabilitation. J Pak Med Assoc. 2022 Aug;72(8):1672-1674. doi: 10.47391/JPMA.22-90. PubMed 36280946 ↗
  • Dockx K, Bekkers EM, Van den Bergh V, Ginis P, Rochester L, Hausdorff JM, Mirelman A, Nieuwboer A. Virtual reality for rehabilitation in Parkinson's disease. Cochrane Database Syst Rev. 2016 Dec 21;12(12):CD010760. doi: 10.1002/14651858.CD010760.pub2. PubMed 28000926 ↗
  • Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381-96. doi: 10.1146/annurev-med-012309-103958. PubMed 21090962 ↗
  • Drossman DA, Tack J, Ford AC, Szigethy E, Tornblom H, Van Oudenhove L. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018 Mar;154(4):1140-1171.e1. doi: 10.1053/j.gastro.2017.11.279. Epub 2017 Dec 22. PubMed 29274869 ↗
  • Trindade MFD, Viana RA. Effects of auditory or visual stimuli on gait in Parkinsonic patients: a systematic review. Porto Biomed J. 2021 Aug 4;6(4):e140. doi: 10.1097/j.pbj.0000000000000140. eCollection 2021 Jul-Aug. PubMed 34368491 ↗
  • Mak MKY, Wong-Yu ISK. Exercise for Parkinson's disease. Int Rev Neurobiol. 2019;147:1-44. doi: 10.1016/bs.irn.2019.06.001. Epub 2019 Jun 27. PubMed 31607351 ↗
  • Tang X, Huang Z, Zhu G, Liang H, Sun H, Zhang Y, Tan Y, Cui M, Gong H, Wang X, Chen YH. Matching supplementary motor area-primary motor cortex paired transcranial magnetic stimulation improves motor dysfunction in Parkinson's disease: a single-center, double-blind randomized controlled clinical trial protocol. Front Aging Neurosci. 2024 Aug 1;16:1422535. doi: 10.3389/fnagi.2024.1422535. eCollection 2024. PubMed 39149144 ↗
  • Frazzitta G, Ferrazzoli D, Folini A, Palamara G, Maestri R. Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors. Front Neurol. 2019 Jun 18;10:621. doi: 10.3389/fneur.2019.00621. eCollection 2019. PubMed 31275225 ↗
  • Fayyaz M, Jaffery SS, Anwer F, Zil-E-Ali A, Anjum I. The Effect of Physical Activity in Parkinson's Disease: A Mini-Review. Cureus. 2018 Jul 18;10(7):e2995. doi: 10.7759/cureus.2995. PubMed 30245949 ↗
  • Yu QJ, Yu SY, Zuo LJ, Lian TH, Hu Y, Wang RD, Piao YS, Guo P, Liu L, Jin Z, Li LX, Chan P, Chen SD, Wang XM, Zhang W. Parkinson disease with constipation: clinical features and relevant factors. Sci Rep. 2018 Jan 12;8(1):567. doi: 10.1038/s41598-017-16790-8. PubMed 29330419 ↗
  • Cataldi S, Bonavolonta V, Poli L, Clemente FM, De Candia M, Carvutto R, Silva AF, Badicu G, Greco G, Fischetti F. The Relationship between Physical Activity, Physical Exercise, and Human Gut Microbiota in Healthy and Unhealthy Subjects: A Systematic Review. Biology (Basel). 2022 Mar 21;11(3):479. doi: 10.3390/biology11030479. PubMed 35336852 ↗
  • Gao X, Zhang P. Exercise perspective: Benefits and mechanisms of gut microbiota on the body. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Apr 28;49(4):508-515. doi: 10.11817/j.issn.1672-7347.2024.230550. Chinese, English. PubMed 39019779 ↗
  • Mach N, Fuster-Botella D. Endurance exercise and gut microbiota: A review. J Sport Health Sci. 2017 Jun;6(2):179-197. doi: 10.1016/j.jshs.2016.05.001. Epub 2016 May 10. PubMed 30356594 ↗
  • Sohail MU, Yassine HM, Sohail A, Thani AAA. Impact of Physical Exercise on Gut Microbiome, Inflammation, and the Pathobiology of Metabolic Disorders. Rev Diabet Stud. 2019;15:35-48. doi: 10.1900/RDS.2019.15.35. Epub 2019 Aug 4. PubMed 31380886 ↗
  • Gubert C, Kong G, Renoir T, Hannan AJ. Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases. Neurobiol Dis. 2020 Feb;134:104621. doi: 10.1016/j.nbd.2019.104621. Epub 2019 Oct 16. PubMed 31628992 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 25, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Oct 20, 2027
CompletionEst.
Oct 20, 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07434089
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Collaborators
Università degli studi di Messina
Responsible party
Maria Lui (Principal Investigator, IRCCS Centro Neurolesi Bonino Pulejo) — Principal investigator
First posted
Feb 25, 2026
Start date
Oct 20, 2025
Primary completion
Oct 20, 2027 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
Feb 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion